Lilly's Third-Quarter Revenue Rose 39% to $24.4 Billion as Mounjaro Hit $10.7 Billion and Zepbound $5.4 Billion
Eli Lilly raised its 2026 revenue forecast to $91 billion to $92 billion, up from $85 billion to $87 billion. Mounjaro sales grew 65%, with $5.7 billion from outside the U.S., Zepbound grew 49%, and the oral GLP-1 Foundayo brought in $184 million. Lilly trimmed its full-year non-GAAP earnings guidance to $35.00 to $36.00 per share after $4.57 per share of acquired research charges in the quarter.